Our finding that CPEB3 in high grade gliomas is expressed as a splice variant that cannot be activated by phosphorylation suggests that it might contribute to altered protein expression in these tumors and be considered an attractive target for new therapeutic strategies. Here, CPEB3 is linked to central nervous system cancer.